US FDA approved Rukobia (fostemsavir) for HIV patients who have limited treatment options

JANSSEN STOPPED PHASE 3 TRIAL OF ITS BLOCKBUSTER

US FDA approved Epizyme’s Tazverik for Relapsed/Refractory Follicular Lymphoma

Eli Lilly Lyumjev secures the US FDA approval for type-1 and type-2 diabetes

Novartis Ilaris to be the first FDA approved treatment for Adult-Onset Still’s Disease (AOSD)

FDA approved Novartis Cosentyx and Lilly’s Taltz for nr-axSpA in June

Viela Bio’s Uplizna received FDA approval for neuromyelitis optica spectrum disorder

Opdivo approved in the US for ESCC

Taltz was approved in the U.S. for non-radiographic axial spondyloarthritis

FDA approved Merck’s Recarbrio to treat hospital acquired pneumonia

Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients

Deciphera Pharmaceuticals’ Qinlock (ripretinib) received the US FDA approval for advanced GIST

FDA approved Novartis’ Tabrecta for NSCLC with METex14

PFIZER AND BIONTECH STARTS THE CLINICAL TRIALS OF COVID-19 VACCINE

AstraZeneca’s approved Koselugo by US FDA for neurofibromatosis type 1

FDA approved a new treatment for a rare soft tissue cancer, epithelioid sarcoma

Trump administration takes first step in implementing provisional law to control drug prices